Pfizer Recognizes Importance of Certification of Physician Investigators
Pfizer recognized the Certified Physician Investigator designation obtained through the Association of Clinical Research Professionals' (ACRP) Certification Program as an acceptable method for clinical investigators to demonstrate competency in good clinical practice (GCP) for Pfizer-sponsored clinical trials.
The decision recognizes the importance of high-quality training in the tenets of GCP to promote physician investigators' safe and ethical conduct of clinical trials with human subjects. Pfizer has reviewed the ACRP Certification Program and says it will recognize the CPI® designation for investigators who wish to conduct Pfizer-sponsored clinical trials.
The examination taken by qualified physicians wishing to earn the CPI® designation is administered by the Academy of Clinical Research Professionals, an affiliate of ACRP that also oversees the Certified Clinical Research Coordinator (CCRC®) and Certified Clinical Research Associate (CCRA®) Certification Programs. The non-profit ACRP was founded in 1976 to promote integrity and excellence in the field and, since 1992, has been the leading certifier of clinical research professionals with more than 24,000 professionals, including nearly 1,100 CPIs, having earned a designation to date.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
